TK2 and hyperinsulinemic hypoglycemia, familial, 4: In any case, this therapy trial gives a lot of hope for future ‘metabolic bypass’ therapies for TK2 deficiency and other FDH disorders: if an exact metabolic defect is identified, targeted metabolite treatment at an early stage of the disease can have dramatic effects.